 |
 |
|
Nissan Chemical entered into the pharmaceutical business in 1982, and introduced an external preparation, ketoprofen (EPATEC) in 1985.
In 1994, efonidipine hydrochloride (LANDEL), a Ca antagonist was launched as our company's first new pharmaceuticals for the indication of hypertension. It was added renoparenchymal hypertension and angina pectoris as its indications in 1998. In South Korea, efonidipine hydrochloride (FINTE) was also introduced in 2003.
Pitavastatin calcium (LIVALO), a statin agent with a strong LDL cholesterol reduction, for the indication of hyperlipidemia was marketed in Japan in 2003. LIVALO is also introduced to South Korea, Thailand, China, the United States and some European countries. It is also planning to be launched in other countries and territories. Global development is steadily progressing.
Concerning the new drug development pipelines, a therapeutic agent for peripheral arterial disease and asthma (NM/NT/INDI-702) is in the process of clinical development in Japan and in the United States. The clinical development with a therapeutic and preventive drug for atrial fibrillation and flutter (NTC-801) has been started in 2007. Further, the clinical development with a new therapeutic agent for thrombocytopenia (NIP-022) has been started in the United States in 2009.
Nissan Chemical keeps trying research and development for innovative medicines by using the strategic chemical library, the state-of-the-art evaluation technology and precise organic synthesis technology. |
|
|
 PHARMACEUTICAL AGENTS
|
|
|
|
| [ LIVALO ] |
|
| LIVALO is a statin agent with a strong LDL cholesterol reduction, which causes less drug-interactions. It is manufactured and distributed by Kowa Company, Ltd., and distributed by Kowa Pharmaceutical Co. Ltd. and Daiichi Sankyo Co., Ltd. in Japan. In South Korea, it is marketed by JW Pharmaceutical Corporation. Choongwae Pharma Corporation. This agent is recognized as one of the "Strong statins" in clinical practice. It is also introduced to Thailand, China, the United States and some European countries. It is also planning to be launched in other countries and territories. |
|
|
 |
|
| [ LANDEL ] |
|
| LANDEL is a dual type Ca antagonist
that blocks not only L-type calcium channels
but also T-type ones. It is distributed
by Zeria Pharmaceutical Co., Ltd. and Shionogi
& Co., Ltd. in Japan. This agent
shows beneficial effects on hypertension
and angina pectoris. In addition, the
agent is expected to show a renal protective
and a cardioprotective effects. |
|
|
|
|
 New Medicines under Development |
| [ NT/NM/INDI-702 ] |
|
| This agent has both a phosphodiesterase inhibitory
effect and a thromboxane A2 synthetase inhibitory effect, and is under
development with Taisho Pharmaceutical Co.,
Ltd. in Japan. Clinical trials not
only for intermittent claudication associated
with peripheral arterial disease but also
asthma are under way. We have entered
a license agreement with Indigo Pharmaceuticals,
Inc. (INDIGO), and have granted INDIGO exclusive
development and marketing rights worldwide,
except in Japan, South Korea, China and Taiwan.
INDIGO prepares to begin Phase III
clinical trials for intermittent claudication. |
|
|
|
|
| [ NTC-801 ] |
|
| NTC-801 is a new antiarrhythmic agent that inhibits the acetylcholine-activated pottasium channel current (IKACh). Because IKACh channel is apparent in the atrium but not in the ventricle, NTC-801 has the potential to be an atrial selective agent for the treatment of atrial fibrillation. In Japan, NTC-801 is currently under Phase II clinical trial with Teijin Pharma Limited. Outside of Japan, we have executed a licensing agreement with Bristol-Myers Squibb Company (BMS), and have granted BMS exclusive development and marketing rights worldwide, except in Japan. Clinical trial is conducted in the United States by BMS. |
|
|
|
| [ NIP-022] |
|
| NIP-022 is an orally active agent which
may increase platelet count by activating
a receptor of thrombopoietin. We and
Ono Pharmaceuticals Co. Ltd. (Ono) entered
into a license agreement in December 2007,
and are jointly developing the agent worldwide.
Phase I clinical trial is conducted
in the United States by Ono (Ono's development
code: ONO-7746). |
|
|
|
|
|
IR Library
Basic Chemicals
